Population pharmacokinetics of liposomal daunorubicin in children
نویسندگان
چکیده
منابع مشابه
Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t1/2 ), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (Cmax ) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal-IRI was performed for tIRI and total SN-38 (tSN38) using patient samples from six studies. PK-safety association was...
متن کاملLiposomal daunorubicin as treatment for Kaposi’s sarcoma
Anthracycline compounds including daunorubicin are the foundation of many modem chemotherapeutic regimens. However, the side-effects of these compounds can be severe, leading to alopecia, nausea, immune deficiency, and cardiotoxicity. For immunocompromised patients with aggressive Kaposi's sarcoma (KS), these complications often preclude the completion of appropriate chemotherapeutic regimens. ...
متن کاملPopulation pharmacokinetics of omeprazole in a random Iranian population
Background: Omeprazole is metabolized predominantly by CYP2C19, a polymorphically expressed enzymes that show marked interindividual and interethnic variation. These variations cause a substantial differences that have been reported in the pharmacokinetics of omeprazole. The aim of the present study was to evaluate the pharmacokinetic parameters of omeprazole in a random Iranian population. Met...
متن کاملPharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma.
In the early 1980s, we first began to see cases of Kaposi's sarcoma (KS) in patients with the lymphadenopathy now known to be associated with infection by the human immunodeficiency virus (HIV). During that period, we were still looking at strong combinations of chemotherapeutic drugs to combat this disease, based on experience in nonimmunosuppressed African patients. It rapidly became apparent...
متن کاملPhase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
BACKGROUND To assess the response rate, toxicity and survival in patients with malignant pleural mesothelioma treated with liposomal daunorubicin. The study design allowed for dose escalation pending toxicity. PATIENTS AND METHODS Liposomal daunorubicin (DaunoXome, Nexstar, USA) 120 mg/m2 was administered every 21 days to a maximum of 6 cycles. Patients had to have histologically-proven malig...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Clinical Pharmacology
سال: 2003
ISSN: 0306-5251
DOI: 10.1046/j.1365-2125.2003.01886.x